Latest Headlines
-
Federal Equipment Company Announces Exclusive Sale Of Brand-New Aseptic Processing & Sterilization Equipment
10/2/2025
Federal Equipment Company is pleased to announce the exclusive consignment of a suite of brand-new, never-used equipment designed for pharmaceutical and biotech aseptic processing. These state-of-the-art systems from leading manufacturers are now available for immediate purchase, offering buyers a unique opportunity to acquire high-performance technologies without the typical lead times of new builds.
-
Precision Biologics Manufacturing Expands U.S. Production with Nevada Groundbreaking
10/1/2025
Precision Biologics Manufacturing, a New Horizon Medical Solutions (NHMS) company, announced a groundbreaking for its manufacturing facility, to develop advanced biologics technology and to bring MedTech jobs to Southern Nevada. Operated by Precision Biologics Manufacturing, the center will expand U.S.-based biologics production and create more than 200 to 300 healthcare-centric jobs in the Las Vegas Valley beginning in the second half of 2026.
-
ROSS Ribbon Blender Optimized For Efficient Powder Handling
9/30/2025
Customizable ROSS Ribbon Blenders deliver reliable mixing of food, nutraceuticals, cosmetics, personal care products, in addition to chemicals, plastics, building materials and agricultural products.
-
Bora Pharmaceuticals Introduces High-Potency Liquid Capsule Technology In Taiwan
9/30/2025
Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, has announced the addition of liquid-filled hard capsule (LFC) production capabilities at its Zhunan, Taiwan facility.
-
Amgen Announces Significant Investment Into Puerto Rico Drug Manufacturing Site
9/26/2025
The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process.
-
Wombat Capital Markets Advised Regis Technologies On Its Sale To Esteve
9/26/2025
This strategic move allows ESTEVE CDMO a physical presence in the U.S., expanding its contract development and manufacturing solutions for innovative small-molecule APIs across the entire drug development lifecycle from pre-clinical to commercial manufacturing.
-
Ritedose Scales Operations With $17M Laboratory Expansion
9/25/2025
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
-
Praxis Packaging Solutions Expands With Acquisition Of Advanced Concept Innovations, LLC
9/25/2025
The strategic combination with ACI further enhances Praxis’ customer oPering by broadening Praxis’ geographic footprint into the Southeastern United States, expanding its capabilities and market segments.
-
PolyPeptide Strengthens Global Peptide Production With Modular Facility Design Approach
9/24/2025
PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation of pre-built modules at its Malmö, Sweden facility. This marks a key milestone in the company’s modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity.
-
$60M Series B Financing Propels Avenzo Therapeutics Forward
9/24/2025
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the closing of a $60 million Series B financing. This funding, which follows Avenzo’s $386 million Series A/A-1 financing announced in November 2024, brings the total capital raised to $446 million. The proceeds will be used to support the advancement of Avenzo’s pipeline of potential best-in-class oncology drug candidates.